A5057897729- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- Cardiac electrophysiology and arrhythmias
- Cardiac Fibrosis and Remodeling
- Drug-Induced Ocular Toxicity
- Peptidase Inhibition and Analysis
- Signaling Pathways in Disease
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Cardiovascular Function and Risk Factors
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Single-cell and spatial transcriptomics
- CAR-T cell therapy research
- Cardiomyopathy and Myosin Studies
Tokyo National Hospital
2022-2025
Nagoya University
2024-2025
Abstract Purpose Tiragolumab is a monoclonal antibody that binds to the inhibitory immune checkpoint TIGIT (T-cell immunoreceptor with Ig and ITIM domains). In early phase clinical trials, tiragolumab in combination programmed death-ligand 1-inhibitor atezolizumab was well tolerated has demonstrated preliminary anti-tumor activity patients advanced/metastatic solid tumors. We report results of I study plus Japanese (jRCT2080224926). Methods ≥ 20 years old received (600 mg) (1200...
Despite the efficacy of many therapies for heart failure, it remains a leading cause morbidity and mortality worldwide, with patients progressing to advanced stages condition. Since standard treatment failure includes small-molecule drugs targeting G protein-coupled receptors (GPCRs), GPCRs are still considered novel targets diagnosis cardiovascular diseases. Corticotropin-releasing hormone receptor 2, highly expressed GPCR in cardiomyocytes, its ligand, urocortin2 (UCN2), have been...
Abstract The first‐in‐human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum‐resistant ovarian non‐small cell lung cancer. A pharmacometric assessment evaluated pharmacokinetics exposure–response (E‐R) relationships for efficacy to support dose optimization. Patients received 0.3‐1.2 mg/kg intravenously every 3 weeks. (PK) model was developed used E‐R analyses. Efficacy assessed via tumor response known...
Abstract Background: SMARCA4 (BRG1) alterations occur in ∼7% and 10% of all solid tumors NSCLC, respectively, are associated with worse overall survival.1, 2 mutations create a dependency on SMARCA2 (BRM), resulting synthetic lethality when is selectively inhibited.3 LY4050784 an oral, potent, selective inhibitor that has demonstrated robust single-agent tumor regressions across multiple murine xenograft models SMARCA4-mutated NSCLC.4 Methods: This first-in-human, phase 1a/b open-label,...
Chronic fibrotic tissue disrupts various organ functions. Despite significant advances in therapies, mortality and morbidity due to heart failure remain high, resulting poor quality of life. Beyond the cardiomyocyte-centric view failure, it is now accepted that alterations interstitial extracellular matrix (ECM) also play a major role development failure. Here, we show protein kinase N (PKN) expressed cardiac fibroblasts. Furthermore, PKN mediates conversion fibroblasts into myofibroblasts,...
Summary Ocular toxicities arising from anti-cancer drugs occur sporadically and are sometimes underestimated because they not life-threatening. Reports focusing on ocular cancer therapy limited. We investigated the detailed progress of including first-in-class ones. A retrospective review medical records was conducted for patients who were involved in early phase clinical trials with scheduled ophthalmologic examinations according to their protocols between January 2014 August 2021. Patients...
12133 Background: Hepatitis, as an immune-related adverse event (irAE), occurs in 2%-10% of patients treated with immune checkpoint inhibitors (ICIs). Although guidelines recommend the use mycophenolate mofetil (MMF) for steroid-refractory and steroid-resistant ir-hepatitis, there has been no evidence on efficacy MMF. Methods: We retrospectively reviewed consecutive solid tumors who developed grade 2 or higher ir-hepatitis requiring systemic steroids after ICIs (nivolumab, pembrolizumab,...
Protein phosphorylation, controlled by protein kinases, is central to regulating various pathophysiological processes, including cardiac systolic function. The dysregulation of kinase activity plays a significant role in the pathogenesis dysfunction. While contraction mechanisms are well documented, underlying diastole remain elusive. This gap persists owing historical focus on dysfunction heart failure research. Recently, with preserved ejection fraction (HFpEF), an age-related disease...
In first-in-human (FIH) trials, sequential tumor biopsies, i.e., two consecutive the first performed at baseline (pretreatment) and second during early treatment period (on-treatment), provide proof of concept in investigational new drugs. We evaluated success biopsies FIH explored approaches for improved rates. retrospectively reviewed required 17 52 trials conducted from 2015 to 2020. One hundred thirty-eight patients were identified. Success either pretreatment or on-treatment biopsy...